Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme LLC
Description:
There will be an estimated 21,410 new cases of ovarian cancer this
year in the United States, and an estimated 13,770 deaths due to
ovarian cancer in the US, according to the American Cancer Society.
Ovarian cancer is usually found late, stage 3 or higher, where it
has already spread or metastasized to other parts of the abdomen, or
worse. This is due in large part to a lack of symptoms during the
earlier stages. The five year survival rate is only 45%. Fortunately
for patients with ovarian cancer, the treatment paradigm has
exploded in the past three years, giving medical directors and
clinicians more options in managing patients with ovarian cancer.
Leading the way in new options for ovarian cancer are poly
(ADP-ribose) polymerase (PARP) inhibitors, which have shown improved
efficacy for patients with ovarian cancer. Additionally, new
indications for these targeted agents offer expanded options in the
maintenance setting in varying lines of therapy. It is important for
medical directors, oncologists, and nurses who manage ovarian cancer
patient populations to have a solid understanding of the mechanistic
rationale for the use of these medications in order to optimize
their therapeutic application.
Upon completion of this
activity, participants will be able to:
-
Examine the clinical and economic
burden of ovarian cancer in terms of relative survival,
mortality, drug utilization, adverse event management, and
hospitalizations
-
Review the DNA damage response (DDR)
pathway and its role in tumorigenesis of ovarian cancers and
outline the various mutations that cause defects in this pathway
-
Incorporate germline and somatic
genetic, genomic, and other biomarker testing that is necessary
to inform treatment decision-making in ovarian cancer
-
Analyze current and emerging
clinical data regarding the safety and efficacy of PARP
inhibitors in ovarian cancer in a variety of settings, including
maintenance
-
Compare and contrast adverse events
associated with PARP inhibitors in the management of ovarian
cancer in order to maximize tolerability and adherence to
therapeutic regimens
-
Assess methods to enable optimal
cost management of PARP inhibitors to be realized by multiple
ovarian cancer stakeholders including managed care organizations
|
Faculty: |
Richard T. Penson, MD,
MRCP
Associate Professor of Medicine HMS
Clinical Director Medical Gynecologic Oncology
IRB Chair DF/HCC |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Penson has served on an advisory board for
AstraZeneca, GlaxoSmithKline, ImmunoGen, Merck, Mersana,
Novacure, Roche, Sutro Biopharma, and Vascular Biogenics.
His presentation has been reviewed for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme LLC
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |